Indication: Gynecologic Cancer
A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination with Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients with Advanced Solid Tumors
Sub-indication: Gynecologic Cancer
Drug Study
Principal Investigator: Mary Gordinier, M.D.Norton Cancer Institute
Sponsor: Sumitomo Dainippon Pharma Oncology, Inc.
Email for more information: GYN-NCIResearch@nortonhealthcare.org
